Tritanium® X TL Expandable Curved Posterior Lumbar Cage
Device Facts
| Record ID | K200613 |
|---|---|
| Device Name | Tritanium® X TL Expandable Curved Posterior Lumbar Cage |
| Applicant | Stryker Corporation |
| Product Code | MAX · Orthopedic |
| Decision Date | Apr 15, 2020 |
| Decision | SESE |
| Submission Type | Special |
| Regulation | 21 CFR 888.3080 |
| Device Class | Class 2 |
| Attributes | Therapeutic |
Indications for Use
The Tritanium® X PL Expandable Posterior Lumbar Cage and Tritanium® X TL Expandable Curved Posterior Lumbar Cage are intended for intervertebral body fusion with autograft and/or allogenic bone graft comprised of cancellous and/or corticocancellous bone graft when the subject device is used as an adjunct to fusion in patients with degenerative disc disease (DDD) at one level or two contiguous levels from L2 to S1. DDD is defined as back pain with degeneration of the disc confirmed by history and radiographic studies. These DDD patients may also have up to Grade I spondylolisthesis or retrolisthesis at the involved level(s). These patients should be skeletally mature and have completed six months of non-operative treatment. Additionally, the Tritanium® X PL Expandable Posterior Lumbar Cage and Tritanium® X TL Expandable Curved Posterior Lumbar Cage can be used as an adjunct to fusion in patients diagnosed with degenerative scoliosis. The Tritanium® X PL Expandable Posterior Lumbar Cage and Tritanium® X TL Expandable Curved Posterior Lumbar Cage are always to be used with supplemental internal spinal fixation. Additionally, the Tritanium® X PL Expandable Posterior Lumbar Cage and Tritanium® X TL Expandable Curved Posterior Lumbar Cage are to be used with autograft and/or allogenic bone graft comprised of cancellous bone graft when the subject device is used as an adjunct to fusion.
Device Story
Hydraulically expandable interbody fusion device; used as adjunct to spinal fusion; implanted in lumbar spine (L2-S1). Device features graft windows for bone packing; serrated superior/inferior surfaces for fixation. Implanted by surgeons; requires supplemental internal spinal fixation. Provides structural support to intervertebral space; promotes fusion via bone graft. Subject device adds 8-10mm height option to existing Tritanium TL cage range.
Clinical Evidence
No clinical data. Bench testing only: subsidence testing per ASTM F2267-04(2018) and impaction testing performed. Risk review conducted to evaluate impact of new size on existing system verification/validation data.
Technological Characteristics
Hydraulically expandable interbody fusion cage. Features graft windows and serrated surfaces. Materials are established/well-known. Dimensions: 12mm width, 32mm length, 8-10mm height. Mechanical testing per ASTM F2267-04(2018).
Indications for Use
Indicated for skeletally mature patients with degenerative disc disease (DDD) at one or two contiguous levels (L2-S1) or degenerative scoliosis. DDD defined as back pain with disc degeneration confirmed by history/radiography; may include up to Grade I spondylolisthesis or retrolisthesis. Requires 6 months non-operative treatment. Must be used with supplemental internal spinal fixation and bone graft.
Regulatory Classification
Identification
An intervertebral body fusion device is an implanted single or multiple component spinal device made from a variety of materials, including titanium and polymers. The device is inserted into the intervertebral body space of the cervical or lumbosacral spine, and is intended for intervertebral body fusion.
Special Controls
*Classification.* (1) Class II (special controls) for intervertebral body fusion devices that contain bone grafting material. The special control is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intervertebral Body Fusion Device.” See § 888.1(e) for the availability of this guidance document.(2) Class III (premarket approval) for intervertebral body fusion devices that include any therapeutic biologic (e.g., bone morphogenic protein). Intervertebral body fusion devices that contain any therapeutic biologic require premarket approval. (c) *Date premarket approval application (PMA) or notice of product development protocol (PDP) is required.* Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.
Predicate Devices
- Tritanium® X PL Expandable Posterior Lumbar Cage and Tritanium® X TL Expandable Curved Posterior Lumbar Cage (K183249)